Early Phase 1 N=21 Bronchoscopic Cryo-Immunotherapy of Lung Cancer
Advanced Non-small Cell Lung Cancer
Primary: Percentage of Successful Performances Among Patients in Whom BCI is Attempted — 100 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=13 Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia Nervosa
Primary: Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI)…
Early Phase 1 N=36 Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
Keratoconus · Dry Eye · Allergy
Primary: Determine the Effect of Dexamethasone Intracanalicular Insert on Patients With Keratoconus Who Also Have Allergies — 1.67; 2 papillary grade
Early Phase 1 N=8 Neurobehavioral Mechanisms of Cocaine Choice
Cocaine Use Disorder
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 110; 98; 90 number of choices
Early Phase 1 N=11 Transgender Estradiol
Transgender Persons
Primary: Maximum Serum Concentration of Estradiol — 144; 35 pg/mL
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
Early Phase 1 N=9 Virtual Reality Exercise in a Community Highschool for Children With Disabilities
Disability Physical · Developmental Disability · Physical Inactivity
Primary: Attendance — 84.4; 31.9 percentage of total sessions attended
Early Phase 1 N=50 Evaluation of Prototype for Simulation for Environmental Exposure Education (SE3)
Effect of Game in Increasing Environmental Health Literacy
Primary: Change in Environmental Health Indoor Air Pollution Knowledge Score — 1.38 score on a scale — p=.042
Early Phase 1 N=30 Melatonin in Patients With Multiple Sclerosis (MS).
Relapsing Remitting Multiple Sclerosis
Primary: Urine Melatonin Levels — 19; 22; 925; 1,687 nanograms per gram of creatinine
Early Phase 1 N=144 Inflammation and Daily Life Study
Inflammation
Primary: Loneliness — 47.9; 46.9; 46.8; 44.6 score on a scale
Early Phase 1 N=118 Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
Antibiotic-associated Diarrhea
Primary: Change From Baseline Levels of Fecal Short-chain Fatty Acid (With a Particular Focus on Acetate) — 23.55; -13.9; -19.5; 7.25 micromolar
Early Phase 1 N=453 Endovascular Recanalization and Standard Medical Management for Symptomatic Nonacute Intracranial Artery Occlusion Trial
Intracranial Artery Occlusion With Infarction
Primary: Primary Outcome — 27; 21 Participants
Early Phase 1 N=27 IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells
Early Phase 1 N=33 Mechanisms for Restoration of Hypoglycemia Awareness
Type1 Diabetes Mellitus
Primary: Brain Glucose Levels — 2.45; 2.16 Mmol/L — p=0.907
Early Phase 1 N=13 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Ichthyosis
Primary: Reduction in Total Ichthyosis Severity Score — -12.2 units on a scale